Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.
J Clin Endocrinol Metab. 2023 Oct 18;108(11):2852-2861. doi: 10.1210/clinem/dgad279.
Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy. Dysregulated expression of miR-146b and androgen receptor (AR) has been shown to play critical roles in tumorigenesis in PTC. However, the mechanistic and clinical association between AR and miR-146b is not fully understood.
The purpose was to investigate miR-146b as the potential AR target miRNA and its involvement in advanced tumor characteristics of PTC.
Expression of AR and miR-146b were assessed in frozen and formalin-fixed paraffin-embedded tissue samples from PTC and adjacent normal thyroid specimens by quantitative real-time polymerase chain reaction, and their correlation was examined. Human thyroid cancer cell lines BCPAP and TPC-1 were used to evaluate the effect of AR on miR-146b signaling. Chromatin immunoprecipitation (ChIP) assays were performed to determine whether AR binds to the miR-146b promoter region.
Pearson correlation analysis confirmed significant inverse correlation between miR-146b and AR expression. Overexpressing AR BCPAP and TPC-1 cells showed relatively lower miR-146b expression. ChIP assay revealed that AR might bind to the androgen receptor element located on the promoter region of miRNA-146b gene, and overexpression of AR suppresses miR-146b-mediated tumor aggressiveness. The low AR/high miR-146b PTC patient group was associated with advanced tumor characteristics, including higher tumor stage, lymph node metastasis, and worse treatment response.
To sum up, miR-146b is a molecular target of AR transcriptional repression; therefore, AR suppresses miR-146b expression to reduce PTC tumor aggressiveness.
甲状腺乳头状癌(PTC)是最常见的甲状腺恶性肿瘤。miR-146b 和雄激素受体(AR)的失调表达已被证明在 PTC 的肿瘤发生中起关键作用。然而,AR 和 miR-146b 之间的机制和临床关联尚未完全阐明。
本研究旨在探讨 miR-146b 作为 AR 潜在的靶 miRNA 及其在 PTC 晚期肿瘤特征中的作用。
通过实时定量聚合酶链反应(qRT-PCR)评估 PTC 及相邻正常甲状腺组织冷冻和福尔马林固定石蜡包埋组织样本中 AR 和 miR-146b 的表达,并检测其相关性。使用人甲状腺癌细胞系 BCPAP 和 TPC-1 评估 AR 对 miR-146b 信号的影响。进行染色质免疫沉淀(ChIP)实验以确定 AR 是否与 miR-146b 启动子区域结合。
Pearson 相关分析证实 miR-146b 与 AR 表达之间存在显著的负相关。过表达 AR 的 BCPAP 和 TPC-1 细胞显示相对较低的 miR-146b 表达。ChIP 实验表明,AR 可能结合位于 miRNA-146b 基因启动子区域的雄激素受体元件,并且 AR 的过表达抑制了 miR-146b 介导的肿瘤侵袭性。AR 低/miR-146b 高的 PTC 患者组与晚期肿瘤特征相关,包括更高的肿瘤分期、淋巴结转移和较差的治疗反应。
总之,miR-146b 是 AR 转录抑制的分子靶标;因此,AR 抑制 miR-146b 的表达以降低 PTC 肿瘤的侵袭性。